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ABSTRACT 
Objective: To explore the key motivators behind selection of analgesics (non-steroidal anti-inflammatory 
drugs (NSAIDs), paracetamol and complementary medications (CMs)) by patients with osteoarthritis 
(OA). 
Methods: A qualitative study, in which in-depth semi-structured interviews were conducted with 15 OA 
patients, recruited from four general practices in Sydney, Australia. Patients were aged 65 or above, and 
were currently taking, or had recently taken, an NSAID for osteoarthritis.  
Results: Three key themes emerged from the data: reliance, routine and pill load. Reliance: Patients 
were strongly reliant upon NSAIDs because they consistently satisfied their needs. By contrast, they 
were much less reliant upon paracetamol because of uncertainty or scepticism about its effectiveness. 
They were not reliant upon CMs but were willing to take them indefinitely because they were perceived 
as being without risk. Routine and pill load: Many patients took an NSAID, as well as CMs as part of a 
‘daily routine’. By contrast, patients had difficulty developing a routine around using paracetamol at the 
recommended maximum dose because of the implicit frequency of dosing required and an aversion to 
the associated ‘pill load’. 
Conclusion: The results highlight the importance of exploring the perceptions and preferences of 
patients with regard to analgesics for OA. Clinician advice regarding analgesia for OA should take 
account of the possible reliance of the patient upon an NSAID, their medicine routines, and their 
potential concern about the pill load associated, in particular, with paracetamol.   
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KEY POINTS 
 
 Osteoarthritis patients held different attitudes towards NSAIDs, paracetamol and 
complementary medications (CMs), preferring NSAIDS over alternatives 
 Three key themes emerged from the data to explain this preference: 1) reliance on NSAIDS, 2) 
resistance to the 'pill load' of paracetamol and 3) the ability to establish a routine around use of 
NSAIDs and CMs 
 By exploring these motivations, clinicians may promote greater adherence to clinical practice 
guidelines for osteoarthritis. 
 
 
INTRODUCTION 
With the ageing population, OA is predicted to become the fourth leading cause of disability in the 
world by 2020 (1). Two common pharmacological treatments for OA are paracetamol and NSAIDs. 
NSAIDs have been shown to have an efficacy advantage compared with paracetamol in clinical trials 
(2,3). However, whereas paracetamol at maximum dose (4 g/day) is relatively safe, NSAIDs (both non-
selective and COX-2 selective agents) have a range of serious adverse effects, particularly affecting those 
aged 65 and above. These include gastrointestinal ulceration, myocardial infarction, stroke, 
hypertension, renal impairment and cardiac failure (4-6). Among patients over the age of 65, non-aspirin 
NSAID-related peptic ulcer disease contributes to a considerable number of hospitalizations each year 
(7).  
 
Due to the different safety profiles of these treatments, most clinical practice guidelines recommend a 
stepped care approach to OA, with paracetamol being used as initial pharmacological therapy after trial 
of non-pharmacological interventions (5, 8-10). In patients whose symptoms are not controlled by 
paracetamol at the maximum recommended dose, then the guidelines suggest that an NSAID may be a 
suitable alternative to pharmacotherapy depending on the individual patient’s risk profile (5,8-10). The 
limited data that exist concerning adherence to these clinical practice guideline recommendations 
suggest that there is an under-utilization of paracetamol and an inappropriately high usage of NSAIDs 
(11-13). It is important to understand the factors contributing to this pattern of usage given the high 
prevalence of OA and the potential for serious NSAID-induced toxicity in the elderly (14). Many of these 
factors will only be discerned by greater focus on the perceptions and experience of the patient. 
 
In addition to traditional pharmacotherapy, complimentary medications, such as glucosamine and 
chondroitin, are widely used by patients to manage the symptoms of OA (12,15). While little is known 
about why patients use CMs in OA, we do have some knowledge of why people use, or reject the use of, 
paracetamol and NSAID.   
 
A study by Barozzi and Tett involving patients and health professionals found that the key barrier for 
consumers using paracetamol was a lack of awareness that this medicine could be used as long-term 
treatment for OA (16). Conversely, health professionals believed consumer perceptions of 
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ineffectiveness and number of tablets (taking up to eight tablets of paracetamol daily) were important 
impediments to patients taking paracetamol. 
 
A number of studies have explored the reasons patients use NSAIDs for OA. These studies have shown 
that patients take an NSAID to comply with advice given by the doctor, but also importantly because 
pain relief and function are paramount (17-20). Additionally, patients are unsure as to whether other 
medicines, such as paracetamol, are more effective or safer than their current NSAID (17). 
 
In our previous publication based upon the same dataset, it was identified that patients disengage from 
risk-related information and also modulate their perception of risk (21). This minimization of the 
potential for harm associated with use of NSAIDs allows a focus on the obvious benefits (analgesia, 
improved function) and, therefore, a favorable benefit over risk conclusion.  
 
The focus of our previous study was the perceptions of risk associated with use of NSAIDs in patients 
with OA (21). In the present study, we interrogated our data further with the aim of exploring what 
motivated patients to select a particular analgesic (NSAID  - including COX-2 selective NSAID, 
paracetamol and/or CMs). 
 
PATIENTS AND METHODS 
As described in our previous publication, sampling was purposive with patients being recruited from 
four general practices located in Sydney, Australia (21). Patients were included if they had been 
diagnosed with OA by their general practitioner/specialist, were aged at least 65 years, were taking or 
had taken in the past 2 years an oral NSAID for OA, were cognitively unimpaired and were able to 
converse reasonably in English. This group of patients was selected because a substantial proportion of 
OA is managed in primary care and older individuals represent the majority of OA sufferers, and as well 
are at greatest risk for NSAID toxicity (22,23). Patients who met the inclusion criteria were invited by 
their general practitioner to participate in the study. There was no clinical relationship between the 
researchers and participating patients. As this study was initially conceptualized as an examination of 
attitudes towards NSAIDs we did not deliberately include or exclude patients on the basis of their use of 
paracetamol or CMs. 
 
In-depth, face-to-face, semi-structured interviews (45–60 min) were conducted by the same researcher 
(T.Y.M.) over 3 months. As part of the interview, participants were asked about their reasons for using 
or rejecting specific OA medicines, including NSAIDs, paracetamol and CMs. The perceptions of patients 
regarding the effectiveness and safety of these medicines were also explored.  Participants were asked 
about their risk factors for specific NSAID-related adverse effects. Data collection was iterative with data 
analysis, enabling progressive refinement of topics discussed (24). 
 
Using the same interview data that had already been digitally recorded, de-identified and transcribed, 
we interrogated the data from the perspective of our new research question: ‘what motivated these 
patients with OA to use or reject a particular analgesic?’ Using the analysis process of Charmaz (25), our 
initial coding involved line-by-line analysis for emergent themes. Similar themes were grouped together 
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into categories and abstracted into concepts. These codes, categories and concepts were constantly 
compared across transcripts and refined until saturation was reached (that is, that no new themes were 
emerging and all themes were accounted for by existing concepts). Initial coding was undertaken by 
T.Y.M, who kept detailed memos in keeping with the principles of grounded theory. A second researcher 
(K.M.W.) independently analysed 
focal sections of interview transcripts and met with the primary researcher to ensure the emergent 
ideas were grounded in the data. Two researchers (T.Y.M and W.L.) developed the initial categories and 
all researchers contributed to the development of concepts from the codes and categories. 
 
The study was approved by the Human Research Ethics Committee of the University of New South 
Wales (Number 09148). This work was supported, in part, by a Project Grant from the National Health 
and Medical Research Council [568612]. 
 
RESULTS 
Interviews were conducted with fifteen patients (see Table 1). Reliance, routine, and pill burden were 
found to be key themes accounting for the preferred use of NSAIDs over paracetamol at the 
recommended therapeutic dose. These themes were also central to the use of CMs by patients. 
 
Table 1: Participants’ details 
 Number of participants 
Age range  
65-69 4 
70-79 7 
80-89 4 
Gender  
Female 8 
Male 7 
Country of birth  
Australia 9 
Other (England, Scotland, Czechoslovakia, Ukraine, 
Netherlands) 
6 
Education  
Intermediate certificate (Year 10) 5 
Leaving certificate 8 
Post-graduate studies 2 
Occupation  
 5 
Professional 7 
Trade 6 
No history of employment 2 
NSAID use  
Current use 13 
Past use  2 
Current or past use of a non-selective NSAID 
(diclofenac (5), ketoprofen (1), peroxicam (1)) 
7 
Current or past use of a COX-2 selective NSAID 
(celecoxib (4), meloxicam (4)) 
8 
Risk factor/s for NSAID-related Adverse effects 14 
Paracetamol use  
Current use  11 
Past use 2 
No history of use 2 
Use of CMs  
Current use (glucosamine, chondroitin, fish oil, 
and/or magnesium supplement) 
9 
Past use 3 
No history of use 3 
 
Reliance 
Patients believed that their NSAID was consistently effective and doubted that they would respond as 
well to other analgesics. Experience affirmed that an NSAID was the most suitable analgesic for them, 
exemplified by one patient’s phrase:  
 
“It [diclofenac] looks after me” (Male, aged 82).  
 
In this way patients were reliant upon their NSAID, depending heavily on the pain relief provided by the 
medicine. 
 
“After two to three days with two [diclofenac] a day… all my joints are right again, it’s just like 
getting a grease and oil change. It is very effective on me.” (Male, aged 65) 
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“Sometimes… you rush out… and by about 9:30 I know I haven’t taken it [ketoprofen]. 
Everything aches and um so I usually just drop everything and go back home and grab them. It’s 
that pronounced yeah.” (Male, aged 69) 
 
“The only thing I need or like is this [diclofenac].” (Male, aged 65) 
 
The belief by patients in the superiority of their NSAID over other classes of analgesics led a few patients 
to continue taking an NSAID despite developing adverse effects. However, in order to justify their 
continued use, they limited the frequency of dosage and/or each dose to reduce the severity of adverse 
effects. 
 
“I have high blood pressure and… I used to have an ulcer… but when I really have pain I use it 
[meloxicam].” (Female, aged 73) 
 
The above patient had difficult-to-control hypertension. Instead of properly trialing paracetamol, as 
advised by her general practitioner, she decided to continue to take meloxicam, but only for two weeks 
of every month.  
 
“My doctor told me instead of [meloxicam] to use [paracetamol]. I started to use it but it didn’t 
help like [meloxicam]… I just took it for a few days and after I stopped.” (Female, aged 73) 
 
The reliance upon an NSAID was also demonstrated by some patients who continued to take an NSAID 
despite being concerned about the withdrawal of rofecoxib from the market. Rofecoxib was voluntarily 
withdrawn from the pharmaceutical market by the sponsor in 2004 due to safety concerns of an 
increased risk of cardiovascular events (5).  In addition, some patients rejected the advice of friends to 
discontinue NSAID use. 
 
“A lot of people say: ‘You don’t take [diclofenac]’, and I say: ‘Yes I have, and I have been quite 
happy with it for quite a few years’.” (Male, aged 82) 
 
There was only one counter-example, a patient who was reliant upon meloxicam yet ceased it, in part, 
because of fears about the safety of NSAIDs stemming from the rofecoxib withdrawal, albeit their 
effectiveness was not in question.  
 
“They [NSAIDs] are brilliant really and then they stop pains and everything… and if they hadn’t… 
been such stuff in the papers about how bad they were, well you know I probably would have 
kept on taking them.” (Female, aged 78) 
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In contrast to NSAIDs, reliance was not clearly evident in relation to paracetamol. While patients taking 
paracetamol acknowledged that it had a role in the treatment of OA, as suggested by their general 
practitioner, its importance was generally perceived as less than that of their NSAID. Furthermore, while 
they spoke enthusiastically about the effectiveness of the NSAID, they appeared to be less certain that 
paracetamol was effective.  
 
“She [general practitioner] doesn’t like [celecoxib] taken all the time… she prefers Panadol 
Osteo as something regular.” (Female, aged 73) 
 
“If it is not bad I take [paracetamol], if it is really bad I… take [diclofenac].” (Female, aged 72) 
 
“[Paracetamol] Nowhere near as effective.” (Male, aged 69) 
 
Indeed, some patients were so sceptical about the effectiveness of paracetamol they decided not to trial 
it or to prematurely cease using it.  
 
“I don’t think they [paracetamol] do much for me. They might…I have never tried to use them.” 
(Male, aged 65) 
 
Many patients were taking glucosamine, chondroitin and/or other CMs alongside NSAIDs and/or 
paracetamol. Similar to paracetamol, their reliance upon CMs was not as strong as their reliance upon 
their NSAID. Despite being sceptical about the effectiveness of these medicines, most patients were 
willing to take them indefinitely because they perceived them to be possibly beneficial while ultimately 
considering them harmless.  
 
“I figure if it [glucosamine] doesn’t make any difference it’s not going to do any harm.” (Male, 
aged 69) 
 
“I do take chondroitin and glucosamine, but it doesn’t do anything. I am sure it doesn’t but I take 
it anyway, it is supposed to be harmless… Somebody put me onto that but I think it is a waste of 
money.” (Male, aged 65) 
 
Routine 
Daily routine was another important determinant of the use of NSAIDs, paracetamol and CMs by 
patients with OA. For some patients, taking an NSAID was a comfortable daily practice. As these patients 
took their NSAID routinely, they did not question their use of this medicine and instead assumed it 
would continue indefinitely.  
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“I can’t say I have started worrying about it, it is just an accepted thing, I take my [diclofenac] 
every morning and I take one at night before I go to bed.” (Male, aged 82) 
 
“I was more than happy with them [ketoprofen] so why change… So it’s just a routine, every 
four months or so I get another prescription.” (Male, aged 69) 
  
The reliance of patients on the NSAID and the routine of taking the medicine appeared to be mutually 
reinforcing. As they were reliant upon the NSAID, they took it routinely, and this in turn strengthened 
the reliance. Routine, therefore, was integral to ongoing NSAID use, along with efficacy-based reliance. 
 
Similar to their use of an NSAID, patients had become accustomed to taking glucosamine, chondroitin 
and/or other CMs every day. Consequently, as with NSAIDs, they were resistant to changing this routine 
but the rationale was different; a view of inherent safety with potential but not certain benefit. 
 
“Well it’s [glucosamine] not doing me any disadvantages by taking it. It’s all just part of the 
routine.” (Male, aged 69) 
 
“So, I think oh well what’s one pill more or less so I pop the glucosamine. It seems a bit silly in a 
way, but yeah, who knows?” (Female, aged 73) 
 
“I will continue taking it [glucosamine]. Um, hopefully somewhere… in the system it does some 
good, I don’t know.” (Male, aged 67) 
 
Pill load  
By contrast, patients had difficulty developing a routine around paracetamol use at the recommended 
maximum daily dose. Only two of the thirteen patients using this medicine were taking the maximum 
dose. Patients disliked the idea of taking 6 or 8 tablets daily (Panadol Osteo or regular paracetamol, 
respectively) of a single medicine. They associated the ‘pill load’ with being a “pill popper”. It was also 
associated with weakness of character and they believed that they should instead tolerate the pain. 
Others questioned the safety of taking 6 to 8 tablets per day and worried about the development of 
tolerance.  
 
“I just don’t like to take six… that is a lot of medication, um, supposedly it’s quite safe to take six 
a day… do you know if they are quite safe to take six a day?” (Male, aged 67) 
 
“He [general practitioner] said ‘you can take up to eight [paracetamol] a day’ but I have never 
taken eight. It just seems like an awful lot to me. I have taken perhaps four.” (Female, aged 68) 
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DISCUSSION 
The present study provides an interesting comparison between three classes of medicines widely used 
to manage the symptoms of OA, each of which is perceived differently in terms of effectiveness, need, 
ease of routine and perceived pill load. This comparison is illustrated in Table 2. 
 
Table 2: Perceived effectiveness of, reliance upon, routine and perceived pill load associated 
with the use of NSAIDs, paracetamol and CMs for OA 
Feature of analgesic 
class 
NSAIDs Paracetamol CMs 
Perceived 
effectiveness 
High Low to moderate Low 
Degree of reliance Strong Low to moderate Low to moderate 
Strength of routine Strong Very low Moderate 
Perceived pill load Low High  Low 
Overall effect on 
behaviour 
Regular use Use at less than 
maximum dose or 
non-use 
Regular use 
 
The findings of the present study extends previous research by showing that reliance, routine and pill 
load are further contributors to use of NSAIDs in OA, and impediments to use of paracetamol (17-20). In 
this regard, our findings differ from those of Barozzi and Tett who did not find scepticism towards the 
effectiveness of paracetamol and pill load to be barriers to paracetamol use among consumers (16). 
Interestingly, these were the reasons cited by general practitioners and pharmacists in their study about 
the reasons for paracetamol under-utilisation.  
 
Exploration of the perceptions of OA patients with respect to use of glucosamine, chondroitin and/or 
other CMs is a relatively new and important area of inquiry. In keeping with our results, Mikhail et al 
found that many of the patients in their focus group used glucosamine but none found it effective (19). 
Our study provides an explanation for this by demonstrating the power of routine in determining 
medicine use. The willingness of patients to take CMs despite being sceptical about their effectiveness 
suggests that patients have very different expectations of CMs compared to non-CMs, much of this 
relating to the perception that so called ‘natural’ is ‘safe’ or ‘good’ (20). 
 
Interestingly, the themes of reliance and routine emerged from a group of older patients which included 
those averse to medicines in general. As focused upon in our previous research (21), some patients 
disliked taking medicines because of fears surrounding toxicity and addiction. This is a common finding 
in research on analgesia in OA and medicine-taking in general (20, 26-29). In the present study, 
regardless of whether they were skeptical about using medicines, patients were reliant upon their 
NSAID and took it routinely. This suggests that the benefits a patient derives from an NSAID may 
outweigh their general concerns about medicines. It was also interesting to note that our participants 
included patients who had never used another NSAID for OA in the past (n=5), those who had used one 
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other NSAID (n=5) and those who used two or more other NSAIDs (n=5), and, therefore, that these 
medication histories did not appear to have a bearing on the emergent themes. 
 
Implications for adherence to clinical practice guidelines  
 Clinical practice guidelines are generally based on what is accepted to be the best available evidence, 
i.e. stemming from meta-analyses of randomised controlled trials (RCTs). It is well known, however, that 
in practice it is difficult to adhere to clinical practice guidelines because they do not reflect the 
complexity of clinical decision-making and are not always congruent with the preferences of patients 
and doctors (30,31); factors which are infrequently addressed within the context of the trials which 
underpin clinical practice guidelines. The present study highlights the complexity behind non-adherence 
to clinical practice guidelines in the context of the pharmacological management of OA. Our findings 
suggest that non-adherence is not simply a matter that clinicians are not aware of guidelines or that 
patients do not understand the recommendations of clinicians. While patients in this study were 
encouraged to take paracetamol at the maximum dose by their general practitioner, they were 
uncomfortable with this practice. Some, who were advised to limit their use of the NSAID, nevertheless 
continued with this medication because of its proven effectiveness. Consequentially, they took an NSAID 
as part of a daily routine. This finding suggests that personal experience, at least for some patients, may 
be a more important determinant of analgesic use in OA than advice from a medical practitioner.  
 
Clinical/communication implications 
The resistance of patients to take paracetamol at the recommended maximum dose and their routine 
use of NSAIDs have potentially important implications for patient safety. Judicious use of NSAIDs for OA 
is crucial given the high prevalence of cardiovascular, gastrointestinal and renal comorbidities, as well as 
polypharmacy, amongst older patients (14,23,32). If patients are not willing to trial paracetamol or are 
taking suboptimal doses, then they are more likely to initiate NSAID therapy, as well as take larger doses 
of NSAIDs. Furthermore, the practice of patients persisting with NSAID therapy despite the occurrence 
of adverse effects is potentially hazardous. It must be accepted, however, that the close temporal 
relationship between dosage of an NSAID and clinical benefit reinforces ‘routine’ as does the 
convenience and lesser pill burden for NSAIDs as compared to paracetamol.  
 
The reasons for non-adherence to clinical practice guidelines are more complex than generally 
acknowledged, and, therefore, improving adherence is a difficult task. The findings of the present study, 
nonetheless, provide some guidance as to how to achieve this outcome through improved clinician-
patient communication. If a clinician finds that a patient is not yet reliant upon an NSAID, then there is 
an opportunity for the doctor to encourage paracetamol at maximum dose. The clinician could also 
explore any fears relating to this practice and provide reassurance. If, on the other hand, a patient is 
already reliant upon and comfortable with the routine of taking an NSAID, then the clinician could be 
sympathetic to the difficulty of altering the patient’s regimen, but firm about the importance of 
changing a routine deemed to be potentially dangerous. To facilitate this, the clinician could encourage 
the patient to trial both a gradual reduction in NSAID dose and an introduction of a safer alternative, 
such as paracetamol. In settings such as Australia in which patient-centred care and shared decision-
making are promoted as part of the “quality use of medicines”, such discussion needs to take into 
consideration both patient values and clinical practice guidelines (33). In these and comparable settings, 
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a shared decision to use an NSAID and/or paracetamol in a way that is not entirely consistent with 
guidelines might be both clinically and ethically appropriate.  
 
Ultimately, our research highlights the importance of clinicians exploring the perceptions and 
preferences of patients about analgesic use in treating OA. Research suggests that this facet of 
management is too infrequently addressed in general practice; instead, practitioners make assumptions 
about the medication preferences of their patients, thus precluding shared decision-making (34). If 
doctors do not realise how reliant a patient is upon use of an NSAID, or fail to recognise the concerns 
about lack of effectiveness and pill load with regard to paracetamol, then they cannot effectively 
communicate about or support safer analgesic use.  
 
Limitations 
We explicitly sought to interview patients who were taking, or had recently taken, an NSAID for OA. 
Therefore, the emergent themes, reliance, routine and pill load, may be less pertinent to OA patients 
who use NSAIDs on a less regular basis and those who use over-the-counter and/or topical NSAIDs. 
Patients who are comfortable with use of paracetamol at maximum dose presumably have different 
views about the effectiveness of paracetamol and the ease or difficulty of taking paracetamol (at 
maximum dose) routinely. Diverse perceptions might also emerge from a selection of younger patients. 
Each of these considerations warrants further investigation. Nonetheless, these findings are likely to 
have very relevant implications for other elderly patients with OA. Furthermore, the themes here 
elicited may be powerful motivators for use of different drug classes for conditions other than OA.  
 
Future directions 
Future research might include a larger study of older-aged OA patients, with a particular focus on those 
who are taking paracetamol at maximum dose with or without an NSAID (in order to discover factors 
that facilitate adherence to the clinical practice guideline recommendation) and those who are using 
only paracetamol and/or CMs so as to examine possible deterrents to NSAID use. It would also be useful 
to recruit a group of OA patients with severe pain not using any analgesics (i.e. neither paracetamol nor 
NSAIDs) to discover factors that prevent reliance upon and routine use of analgesics. Other research 
might involve recruiting patients with different severity, sites and duration of OA to examine what effect 
these factors have on choice of analgesic and the prominence of the themes of reliance, routine and pill 
load. Other variables of interest would include medication history (e.g. comparing patients who have 
only used one kind of NSAID with those who have used many) and level of education and health literacy.  
 
It would also be interesting to explore with patients the influence of advice from health professionals, 
personal experience, as well as social contacts and the media in shaping their perceptions and 
determining their use of NSAIDs, paracetamol and CMs for OA. In this regard, it would be useful to 
conduct similar research in settings in which patient centred care and shared decision-making are valued 
less than they are in Australia to see whether this corresponds to greater adherence to formal 
guidelines, i.e. greater usage of paracetamol over an NSAID. 
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A study of the attitudes and practices of clinicians would also be informative. Clinicians might also 
become reliant on an individual or specific class of medicine and, therefore prescribe by routine. It is 
well known that positive patient experiences with a specific medicine can reinforce prescribing practice 
(35,36). Exploring the reliance of prescribers on specific medicines and prescribing routines may enable 
identification of strategies to address this additional barrier to clinical practice guideline 
implementation. Importantly, there is a need to better appreciate the limitations imposed when 
medicines are used in the field where toxicity, and especially symptom-free toxicity, may be less 
relevant to the patient than immediacy of effect on the quality of daily living.  
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